Tag Archives: antimicrobial

Consider the business angle when covering antibiotic resistance

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Photo: NIAID via Flickr

In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.

The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.

The problem is a unique business and policy dilemma for society. Continue reading